Open Access
| Issue |
BIO Web Conf.
Volume 174, 2025
2025 7th International Conference on Biotechnology and Biomedicine (ICBB 2025)
|
|
|---|---|---|
| Article Number | 02009 | |
| Number of page(s) | 8 | |
| Section | Innovations in Therapeutics and Disease Mechanisms | |
| DOI | https://doi.org/10.1051/bioconf/202517402009 | |
| Published online | 12 May 2025 | |
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834 [CrossRef] [PubMed] [Google Scholar]
- Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624-639. doi:10.1038/s41571-023-00798-3 [CrossRef] [PubMed] [Google Scholar]
- Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(9):849-861. doi:10.1056/NEJMra1703413 [CrossRef] [PubMed] [Google Scholar]
- Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345-1356. doi:10.1038/s41591-021-01450-2 [CrossRef] [PubMed] [Google Scholar]
- Xia L, Liu Y, Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist. 2019;24(Suppl 1): S31-S41. doi:10.1634/theoncologist.2019-IO-S1-s05 [CrossRef] [PubMed] [Google Scholar]
- Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4. doi:10.1126/scitranslmed.aad7118 [Google Scholar]
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. doi:10.1056/NEJMoa1606774 [CrossRef] [PubMed] [Google Scholar]
- Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med. 2015;372(21):2018-2028. doi:10.1056/NEJMoa1501824 [CrossRef] [PubMed] [Google Scholar]
- Lievense LA, Sterman DH, Cornelissen R,et al.Checkpoint Blockade in Lung Cancer and Mesothelioma. Am J Respir Crit Care Med. 2017;196(3):274-282. doi:10.1164/rccm.201608-1755CI [CrossRef] [PubMed] [Google Scholar]
- Inno A, Marchetti F, Valerio M, et al. Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report. Drug Target Insights. 2023;17:90-91. Published 2023 Jun 20. doi:10.33393/dti.2023.2593 [CrossRef] [PubMed] [Google Scholar]
- Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet. 2021;398(10299):535-554. doi:10.1016/S0140-6736(21)00312-3 [CrossRef] [PubMed] [Google Scholar]
- Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;10.1056/NEJMoa2103695. doi:10.1056/NEJMoa2103695 [Google Scholar]
- Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19(10):637-655. doi:10.1038/s41571-022-00671-9 [CrossRef] [PubMed] [Google Scholar]
- Zhu C, Guan X, Zhang X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159. Published 2022 Aug 4. doi:10.1186/s12943-022-01629-2 [CrossRef] [Google Scholar]
- Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386. Published 2021 Nov 15. doi:10.1038/s41392-021-00780-4 [CrossRef] [Google Scholar]
- Li L, Zhao H, Peng X, et al. Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. Bioorg Med Chem. 2022;71:116962. doi:10.1016/j.bmc.2022.116962 [CrossRef] [Google Scholar]
- Meraz IM, Majidi M, Meng F, et al. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res. 2019;7(8):1267-1279. doi:10.1158/2326-6066.CIR-18-0874 [CrossRef] [PubMed] [Google Scholar]
- Liu X, He S, Wu H, Xie H, Zhang T, Deng Z. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Environ Health Prev Med. 2019 Dec 21;24(1):79. doi: 10.1186/s12199-019-0835-3. PMID: 31864288; PMCID: PMC6925464. [CrossRef] [PubMed] [Google Scholar]
- Liu J, Li J, Tuo Z, Hu W, Liu J. BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non-small cell lung cancer. J Biol Chem. 2023 Nov;299(11):105302. doi:10.1016/j.jbc.2023.105302. Epub 2023 Sep 29. PMID: 37777155; PMCID: PMC10641166. [CrossRef] [Google Scholar]
- Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014 Feb;124(2):687-95. doi: 10.1172/JCI67313. Epub 2014 Jan 2. PMID: 24382348; PMCID: PMC3904601. [CrossRef] [PubMed] [Google Scholar]
- Peng H, Wu X, Liu S, He M, Xie C, Zhong R, Liu J, Tang C, Li C, Xiong S, Zheng H, He J, Lu X, Liang W. Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment. Clin Transl Med. 2023 Jan;13(1):e1155. doi: 10.1002/ctm2.1155. PMID: 36588094; PMCID: PMC9806015. [CrossRef] [Google Scholar]
- Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113-1120. doi:10.1038/ng.2764 [CrossRef] [PubMed] [Google Scholar]
- Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Llorian Sopena M, East P, Ambler R, Anastasiou P, Romero-Clavijo P, Valand K, Cole M, Molina-Arcas M, Downward J. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci Adv. 2022 Jul 22;8(29): eabm8780. doi: 10.1126/sciadv.abm8780. Epub 2022 Jul 20. PMID: 35857848; PMCID: PMC9299537. [CrossRef] [Google Scholar]
- Chour A, Denis J, Mascaux C, Zysman M, Bigay-Game L, Swalduz A, Gounant V, Cortot A, Darrason M, Fallet V, Auclin E, Basse C, Tissot C, Decroisette C, Bombaron P, Giroux-Leprieur E, Odier L, Brosseau S, Creusot Q, Gueçamburu M, Meersseman C, Rochand A, Costantini A, Gaillard CM, Wasielewski E, Girard N, Cadranel J, Lafitte C, Lebossé F, Duruisseaux M. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer. J Thorac Oncol. 2023 Oct;18(10):1408-1415. doi: 10.1016/j.jtho.2023.05.013. Epub 2023 May 20. PMID: 37217096. [CrossRef] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.